About Catylix

Catylix was founded by Professor John Hartwig, Dr. David Rozzell, and Dr. Brian Adger to develop better methods for producing biologically-active compounds with improved pharmacokinetic properties.

One of the most effective ways to improve the pharmacokinetic properties of a bioactive compound is the introduction of a fluorine-containing functional group. Fluorinated substituents have been shown to improve lipid solubility, receptor binding, metabolic stability, and bioavailability, which can dramatically improve the performance of a potential drug.

The company’s first product is a new, shelf-stable reagent for trifluoromethylation, allowing the derivatization of a broad range of compounds with a CF3 group under mild conditions. Catylix plans to expand the chemistries it practices to include additional chemical functionality that improves the properties of compounds targeted for the pharmaceutical and crop protection markets. Services for the preparation of trifluoromethyl-substituted aryl and heterocyclic compounds on a custom basis will also be available.

The ultimate goal is to provide the best methods for broadening the scope of compounds available for medicinal, veterinary and agrochemical applications.